These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 9589248)

  • 1. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
    Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS; Robson MC; Smiell JM; Perry BH
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
    Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
    Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group.
    Steed DL
    J Vasc Surg; 1995 Jan; 21(1):71-8; discussion 79-81. PubMed ID: 7823364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
    Mustoe TA; Cutler NR; Allman RM; Goode PS; Deuel TF; Prause JA; Bear M; Serdar CM; Pierce GF
    Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
    Senet P; Vicaut E; Beneton N; Debure C; Lok C; Chosidow O
    Arch Dermatol; 2011 Aug; 147(8):926-30. PubMed ID: 21482863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC; Phillips LG; Thomason A; Robson LE; Pierce GF
    Lancet; 1992 Jan; 339(8784):23-5. PubMed ID: 1345953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
    J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
    Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Becaplermin gel (Regranex gel)].
    Senet P
    Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.